This study is in progress, not accepting new patients
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Santa Monica, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jonathan Goldman
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Jonathan Goldman
Hs Clinical Professor, Medicine. Authored (or co-authored) 108 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Janssen Research & Development, LLC
- ID
- NCT04538664
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 308 people participating
- Last Updated